Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Spinal Diseases: HELP
Articles by Wilson Bautista Molano
Based on 10 articles published since 2008

Between 2008 and 2019, Wilson Bautista-Molano wrote the following 10 articles about Spinal Diseases.
+ Citations + Abstracts
1 Guideline Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. 2016

Coates, Laura C / Kavanaugh, Arthur / Mease, Philip J / Soriano, Enrique R / Laura Acosta-Felquer, Maria / Armstrong, April W / Bautista-Molano, Wilson / Boehncke, Wolf-Henning / Campbell, Willemina / Cauli, Alberto / Espinoza, Luis R / FitzGerald, Oliver / Gladman, Dafna D / Gottlieb, Alice / Helliwell, Philip S / Husni, M Elaine / Love, Thorvardur J / Lubrano, Ennio / McHugh, Neil / Nash, Peter / Ogdie, Alexis / Orbai, Ana-Maria / Parkinson, Andrew / O'Sullivan, Denis / Rosen, Cheryl F / Schwartzman, Sergio / Siegel, Evan L / Toloza, Sergio / Tuong, William / Ritchlin, Christopher T. ·Leeds Institute of Rheumatic and Musculoskeletal Medicine and University of Leeds, Leeds, UK. · University of California at San Diego. · Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington. · Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. · University of Southern California, Keck School of Medicine, Los Angeles. · Hospital Militar Central and Universidad Militar Nueva Grenada, Bogotá, Colombia. · Geneva University Hospital, Geneva, Switzerland. · Toronto Western Hospital, Toronto, Ontario, Canada. · University of Cagliari, Monserrato Campus, Cagliari, Italy. · Louisiana State University Health Sciences Center, New Orleans. · St. Vincent's University Hospital, The Conway Institute for Biomolecular Research, and University College Dublin, Dublin, Ireland. · University of Toronto and Toronto Western Research Institute, Toronto, Ontario, Canada. · Tufts Medical Center, Boston, Massachusetts. · Leeds Institute of Rheumatic and Musculoskeletal Medicine and University of Leeds, Leeds, UK, and Bradford Hospitals NHS Foundation Trust, Bradford, UK. · Cleveland Clinic Foundation, Cleveland, Ohio. · University of Iceland and Landspitali University Hospital, Reykjavik, Iceland. · University of Molise, Campobasso, Italy. · Royal National Hospital for Rheumatic Diseases, Bath, UK. · University of Queensland, Brisbane, Queensland, Australia. · University of Pennsylvania, Philadelphia. · Johns Hopkins University School of Medicine, Baltimore, Maryland. · Chapel Allerton Hospital, Leeds, UK. · St. Vincent's University Hospital, Dublin, Ireland. · Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada. · Hospital for Special Surgery, New York, New York. · Arthritis and Rheumatism Associates, Rockville, Maryland. · Ministry of Health, San Fernando del Valle de Catamarca, Argentina. · University of California, Davis. · University of Rochester Medical Center, Rochester, New York. ·Arthritis Rheumatol · Pubmed #26749174.

ABSTRACT: OBJECTIVE: To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA). METHODS: GRAPPA rheumatologists, dermatologists, and PsA patients drafted overarching principles for the management of PsA, based on consensus achieved at face-to-face meetings and via online surveys. We conducted literature reviews regarding treatment for the key domains of PsA (arthritis, spondylitis, enthesitis, dactylitis, skin disease, and nail disease) and convened a new group to identify pertinent comorbidities and their effect on treatment. Finally, we drafted treatment recommendations for each of the clinical manifestations and assessed the level of agreement for the overarching principles and treatment recommendations among GRAPPA members, using an online questionnaire. RESULTS: Six overarching principles had ≥80% agreement among both health care professionals (n = 135) and patient research partners (n = 10). We developed treatment recommendations and a schema incorporating these principles for arthritis, spondylitis, enthesitis, dactylitis, skin disease, nail disease, and comorbidities in the setting of PsA, using the Grading of Recommendations, Assessment, Development and Evaluation process. Agreement of >80% was reached for approval of the individual recommendations and the overall schema. CONCLUSION: We present overarching principles and updated treatment recommendations for the key manifestations of PsA, including related comorbidities, based on a literature review and consensus of GRAPPA members (rheumatologists, dermatologists, other health care providers, and patient research partners). Further updates are anticipated as the therapeutic landscape in PsA evolves.

2 Review Comprehensive treatment of dactylitis in psoriatic arthritis. 2014

Rose, Shawn / Toloza, Sergio / Bautista-Molano, Wilson / Helliwell, Philip S / Anonymous5660810. ·From the US National Institutes of Health, Bethesda, Maryland, USA; Rheumatology, Ministry of Health, San Fernando del Valle de Catamarca, Argentina; Department of Rheumatology, Hospital Militar Central, Faculty of Medicine UMNG, Bogotá, Colombia; University of Leeds, Leeds; and Bradford Hospitals NHS Foundation Trust, Bradford, UK.S. Rose, MD, PhD, Metzger Clinical Scholar, National Institutes of Health; S. Toloza, MD, Rheumatology, Ministry of Health; W. Bautista-Molano, MD, PhD(c), Department of Rheumatology, Hospital Militar Central, Faculty of Medicine UMNG; P.S. Helliwell, DM, PhD, FRCP, Senior Lecturer in Rheumatology, University of Leeds and Bradford Hospitals NHS Foundation Trust. Drs. Rose and Toloza contributed equally to this report. ·J Rheumatol · Pubmed #25362714.

ABSTRACT: Dactylitis, a hallmark clinical feature of psoriatic arthritis (PsA) and other spondyloarthropathies, may also be a severity marker for PsA and psoriasis. Traditionally, clinicians have used nonsteroidal antiinflammatory drugs and local corticosteroid injections to treat dactylitis, although conventional disease-modifying antirheumatic drugs are also used. We performed a systematic literature review to determine the most efficacious current treatment options for dactylitis in PsA. Effect sizes were greatest for the biologic agents ustekinumab, certolizumab, and infliximab, suggesting that therapy with one of these agents should be initiated in patients with dactylitis. However, the limited data highlight the need for randomized, placebo-controlled trials, with dactylitis as a primary outcome, to determine a valid, reliable, and responsive clinical outcome measure for PsA patients with dactylitis.

3 Review How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review. 2014

Bautista-Molano, Wilson / Navarro-Compán, Victoria / Landewé, Robert B M / Boers, Maarten / Kirkham, Jamie J / van der Heijde, Désirée. ·Rheumatology Department, C1R, Leiden University Medical Center, PO Box 9600, 2300, RC, Leiden, The Netherlands. ·Clin Rheumatol · Pubmed #24970597.

ABSTRACT: This study aims to investigate how well the Assessment of SpondyloArthritis international Society (ASAS)/Outcome Measures in Rheumatology Clinical Trials (OMERACT) core set and response criteria for ankylosing spondylitis (AS) have been implemented in randomized controlled trials (RCTs) testing pharmacological and non-pharmacological interventions. A systematic literature search was performed up to June 2013 looking for RCTs in patients with axial spondyloarthritis (SpA) (AS and non-radiographic axial SpA). The assessed domains and instruments belonging to the core sets for disease-controlling anti-rheumatic therapy (DC-ART) and symptom-modifying anti-rheumatic drugs (SMARDs) were extracted. Results were reported separately for those trials published until 2 years after the publication of the core set (1 April 2001; 'control trials') and those trials published at least 2 years after the publication date ('implementation trials'). One hundred twenty-three articles from 99 RCTs were included in the analysis, comparing 48 'control trials' and 51 'implementation trials'. Regarding DC-ART core set, the following domains were significantly more frequently assessed in the 'implementation group' in comparison to the 'control group': 'physical function' (100 vs 41.7 %; p ≤ 0.001), 'peripheral joints/entheses' (100 vs 33.3 %; p ≤ 0.001) and 'fatigue' (100 vs 0 %; p ≤ 0.001). Three instruments were significantly more used in the 'implementation group': Bath Ankylosing Spondylitis Functional Index (BASFI) (100 vs 8.3 %; p = ≤ 0.001), CRP (92.3 vs 58.3 %; p = 0.01) and Bath Ankylosing Spondylitis Metrology Index (BASMI) (53.8 vs 0 %; p = 0.001). Regarding SMARD core set domains, physical function (92 vs 23 %; p ≤ 0.001) and fatigue (84 vs 17 %; p ≤ 0.001), as well as the instruments BASFI (88 vs 14 %; p ≤ 0.001) and BASMI (52 vs 0 %; p ≤ 0.001), increased significantly in the 'implementation group'. Twenty per cent of trials from the 'implementation group' but none from the 'control group' included all domains of the core set. In conclusion, this study provides evidence for the implementation of the ASAS/OMERACT core set in RCTs of both DC-ART and SMARD. This applies to the use of the domains and, to a lesser extent, to the specific instruments.

4 Review [Bone remodeling in spondyloarthritis]. 2013

Bautista-Molano, Wilson / Romero-Sánchez, Consuelo / De Ávila, Juliette / Londoño, John / Valle-Oñate, Rafael. · ·Rev Med Chil · Pubmed #24522422.

ABSTRACT: Spondyloarthritis is a group of several related but phenotypically distinct chronic inflammatory diseases, characterized by progressive new bone formation which leads to ankylosis and functional disability. Radiographic images evidence not only erosive changes but also overgrowth of bony structures called syndesmophytes. These inflammation, bone destruction and new bone formation are located in the entheses, which constitutes the primary organ of the disease. As a consequence, the inflammatory process results in excess of bone formation and the impact depends on the location, cell type, cytokines and local microenvironment factors. Several molecules playing a role as immune modulators or regulators of bone homeostasis, mediate the imbalance between bone resorption and formation. In the same way, animal models suggest that joint ankylosis may be independent from the effects of tumor necrosis factor alpha. Therefore, the process of new tissue (bone) formation can be considered as an additional therapeutic target. The Wnt signaling pathway, which is considered the primary regulator of osteoblastogenesis, constitutes a new research field of great interest in the last decade.

5 Article Validation and reliability of translation of the ASAS Health Index in a Colombian Spanish-speaking population with spondyloarthritis. 2018

Bautista-Molano, Wilson / Landewé, Robert B M / Kiltz, Uta / Valle-Oñate, Rafael / van der Heijde, Désirée. ·Rheumatology Department, Leiden University Medical Center, Leiden, The Netherlands. wilson.bautista@gmail.com. · Rheumatology Department, School of Medicine, Universidad Militar Nueva Granada and Hospital Militar, Transversal 3 No. 49-00 3th floor, Bogotá, Colombia. wilson.bautista@gmail.com. · Rheumatology Department Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. · Rheumazentrum Ruhrgebiet, Herne, Germany. · Rheumatology Department, School of Medicine, Universidad Militar Nueva Granada and Hospital Militar, Transversal 3 No. 49-00 3th floor, Bogotá, Colombia. · Rheumatology Department, Leiden University Medical Center, Leiden, The Netherlands. ·Clin Rheumatol · Pubmed #30259248.

ABSTRACT: To validate a Spanish language translation of the ASAS Heath-Index (ASAS-HI) testing, its reliability, construct validity, and responsiveness in Colombian patients with spondyloarthritis. Translation was done following a forward-backward procedure. Patients fulfilling the Assessment of Spondyloarthritis international Society (ASAS) criteria for either axial or peripheral spondyloarthritis (SpA) participated. Test-retest reliability was assessed by intra-class correlation coefficient (ICC) in patients without treatment changes. In patients who required a therapeutic intervention, responsiveness was assessed using the standardized response mean (SRM). Construct validity was evaluated by Spearman correlation. Internal consistency (Cronbach's α) and discriminative ability of the ASAS-HI were assessed. Fifty patients were included: 54% male, mean (SD) age 44.8 (13.1), symptom duration 15.8 (9.7) years, Bath Ankylosing Spondylitis Disease Index (BASDAI) 4.6 (2.2), Bath Ankylosing Spondylitis Functioning Index (BASFI) 4.7 (2.5), Ankylosing Spondylitis Disease Activity Score with C-Reactive Protein (ASDAS-CRP) 2.2 (1.0). Axial SpA was established in 44 patients (ankylosing spondylitis (AS) = 30, non-radiographic axial SpA (nr-axSpA) = 14) and peripheral SpA in 6 patients. The score of the ASAS-HI was 8.2 (5.1). The test-retest reliability was good with an ICC of 0.84. SRM was 2.58 (1.75-3.37) in 10 patients with any intervention and 2.94 (2.13-4.24) for 7 patients starting TNF blockers. Construct validity showed a good correlation between ASAS-HI and pain, BASDAI, BASFI, and Ankylosing Spondylitis Disease Activity Score (ASDAS) (r ≥ 0.60). A high internal consistency was found with a Cronbach's α of 0.91. ASAS-HI discriminated well between patients with different stages of disease activity (BASDAI and ASDAS). Those with higher disease activity had higher ASAS-HI scores. The Spanish language translation of the ASAS-HI has proven to be psychometrically valid for Colombian patients with SpA. This version is available to evaluate the state of health and functioning in these patients and can be used in clinical practice.

6 Article The Frequency of HLA-B27 in a Colombian Population with Signs of Spondyloarthritis. 2018

Romero-Sanchez, Consuelo / Chila-Moreno, Lorena / Gómez, Alberto / Casas G, Maria Consuelo / Bautista-Molano, Wilson / Briceño, Ignacio / Rueda, Juan C / De Avila, Juliette / Londono, John / Valle-Onate, Rafael. ·Spondyloarthropaty Group, Division of Rheumatology, Hospital Militar Central, Bogota, Colombia. · UIBO Institute (Oral Basic Research Unit), Universidad El Bosque, Bogota, Colombia. · Instituto de Referencia Andino, Bogota, Colombia. · Faculty of Medicine, Universidad Militar Nueva Granada, Bogota, Colombia. · Institute of Human Genetics, Faculty of Medicine, Pontificia Universidad Javeriana, Bogota, Colombia. · Faculty of Medicine, Universidad de la Sabana, Bogota, Colombia. · Spondyloarthropaty Group. Universidad de la Sabana-Division of Rheumatology and Immunology, Hospital Militar Central, Bogota, Colombia. ·Curr Rheumatol Rev · Pubmed #28356051.

ABSTRACT: BACKGROUND: The strong association between HLA-B27 and spondyloarthritis (SpA) has demonstrated that typing the HLA-B27 antigen is a crucial step in diagnosis and aids in defining the progression and severity of disease. OBJECTIVE: To describe the frequency of HLA-B27 in Colombian individuals with clinical manifestations associated with SpA. MATERIALS AND METHODOLOGY: We retrospectively analyzed 4109 HLA-B27 typing requests to the Hospital Militar Central and the Instituto de Referencia Andino from Colombian individuals with clinical signs suggestive of SpA between 2009 and 2012. We used basic digital cytometry followed by Polymerase Chain Reaction with sequence specific primers when confirmation was needed. We determined the frequency of HLA-B27 in the population and levels of association of HLA-B27 with SpA. RESULTS: Our population included 1585 men (36.8%) and 2524 women (61.4%). The predominant age range was between 19 and 45 years (49.9%). The majority (95.4%) of the study population came from the Andean region and eastern plains. The most frequent clinical manifestations were peripheral. Only a small fraction (12.1%) of the 4109 subjects was HLA-B27 positive. Of those, 56.9% were male, and 54.7% were between 19 and 45 years old. In contrast, when rheumatologists referred the HLA B27, 64% were found to be positive. CONCLUSION: The frequency of the HLA-B27 allele in individuals with clinical signs suggestive of SpA was low, in accordance with the lower prevalence found in Colombian patients diagnosed with SpA compared to American and European population.

7 Article Factors associated with the decision of the rheumatologist to order sacroiliac joints magnetic resonance imaging (SI-MRI) or HLA-B27 testing in the diagnostic work-up of patients with spondyloarthritis in clinical practice. 2017

Bautista-Molano, Wilson / Landewé, Robert B M / Serna, Cesar / Valle-Oñate, Rafael / van der Heijde, Désirée. ·Rheumatology Department, Leiden University Medical Center, Leiden, The Netherlands; and Rheumatology Department, School of Medicine, HMC/UMNG, Bogotá, Colombia. wilson.bautista@gmail.com. · Rheumatology Department, Academic Medical Center, University of Amsterdam, The Netherlands. · Statistics and Mathematics Department, Universidad Central, Bogotá, Colombia. · Rheumatology Department, School of Medicine, HMC/UMNG, Bogotá, Colombia. · Rheumatology Department, Leiden University Medical Center, Leiden, The Netherlands. ·Clin Exp Rheumatol · Pubmed #27782870.

ABSTRACT: OBJECTIVES: To evaluate the patients' characteristics associated with the clinical decision to request SI-MRI and/or HLA-B27 in patients with SpA in daily practice. METHODS: Patients referred to a rheumatology outpatient-clinic in a national referral-centre were selected. Patients with a clinical diagnosis of SpA according to the rheumatologist were included. SI-MRI and HLA-B27 was available for patients in whom the rheumatologists had ordered these tests. Characteristics associated with ordering SI-MRI or HLA-B27 were identified with univariable analyses. Variables with p-value <0.05 and >80% completeness were selected for further analysis. A multivariable logistic regression analysis was used to evaluate the determinants related with the decision to perform SI-MRI and/or HLA-B27 and odds ratios with 95% confidence intervals were calculated. RESULTS: In total, 581 patients with SpA were included in the cohort, 72% were men, mean age 34.6±12.1 and disease duration 7.3±9.7 years. Of these patients, 24% (n=137) had SI-MRI and 77% (n=441) had HLA-B27 tests ordered. Independently predictive factors for ordering a SI-MRI were the presence of IBP (OR=1.81), enthesitis (OR=1.57) and the number of initial-symptoms at presentation (OR=1.27 per additional symptom present). Independently predictive factors of HLA-B27 testing were the number of initial-symptoms (OR=1.45 per symptom) and uveitis (OR=3.19). CONCLUSIONS: This study strongly suggests that rheumatologists use certain clinical clues to decide if they order expensive and scarce tests in the diagnostic work-up of SpA patients. These manifestations may increase the efficiency of these tests in clinical practice and suggest that clinical reasoning follows principles of Bayesian theory.

8 Article Analysis and performance of various classification criteria sets in a Colombian cohort of patients with spondyloarthritis. 2016

Bautista-Molano, Wilson / Landewé, Robert B M / Londoño, John / Romero-Sanchez, Consuelo / Valle-Oñate, Rafael / van der Heijde, Désirée. ·Rheumatology Department, Leiden University Medical Center, Leiden, The Netherlands. wbatu@hotmail.com. · Rheumatology Department, School of Medicine, HMC/UMNG, Transversal 3 No. 49-00 3th floor, Bogotá, Colombia. wbatu@hotmail.com. · Rheumatology Department, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. · Rheumatology Department, School of Medicine, HMC/UMNG, Transversal 3 No. 49-00 3th floor, Bogotá, Colombia. · School of Medicine and Center for Applied Medical Research, University of Navarra, Pamplona, Spain. · Rheumatology Department, Leiden University Medical Center, Leiden, The Netherlands. ·Clin Rheumatol · Pubmed #26791876.

ABSTRACT: The objective of this study was to investigate the performance of classification criteria sets (Assessment of SpondyloArthritis international Society (ASAS), European Spondylarthropathy Study Group (ESSG), and Amor) for spondyloarthritis (SpA) in a clinical practice cohort in Colombia and provide insight into how rheumatologists follow the diagnostic path in patients suspected of SpA. Patients with a rheumatologist's diagnosis of SpA were retrospectively classified according to three criteria sets. Classification rate was defined as the proportion of patients fulfilling a particular criterion. Characteristics of patients fulfilling and not fulfilling each criterion were compared. The ASAS criteria classified 81 % of all patients (n = 581) as having either axial SpA (44 %) or peripheral SpA (37 %), whereas a lower proportion met ESSG criteria (74 %) and Amor criteria (53 %). There was a high degree of overlap among the different criteria, and 42 % of the patients met all three criteria. Patients fulfilling all three criteria sets were older (36 vs. 30 years), had more SpA features (3 vs. 1 features), and more frequently had a current or past history of back pain (77 vs. 43 %), inflammatory back pain (47 vs. 13 %), enthesitis (67 vs. 26 %), and buttock pain (37 vs. 13 %) vs. those not fulfilling any criteria. HLA-B27, radiographs, and MRI-SI were performed in 77, 59, and 24 % of the patients, respectively. The ASAS criteria classified more patients as having SpA in this Colombian cohort when the rheumatologist's diagnosis is used as an external standard. Although physicians do not perform HLA-B27 or imaging in all patients, they do require these tests if the clinical symptoms fall short of confirming SpA and suspicion remains.

9 Article Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. 2016

Moltó, Anna / Etcheto, Adrien / van der Heijde, Désirée / Landewé, Robert / van den Bosch, Filip / Bautista Molano, Wilson / Burgos-Vargas, Ruben / Cheung, Peter P / Collantes-Estevez, Eduardo / Deodhar, Atul / El-Zorkany, Bassel / Erdes, Shandor / Gu, Jieruo / Hajjaj-Hassouni, Najia / Kiltz, Uta / Kim, Tae-Hwan / Kishimoto, Mitsumasa / Luo, Shue-Fen / Machado, Pedro M / Maksymowych, Walter P / Maldonado-Cocco, José / Marzo-Ortega, Helena / Montecucco, Carlo-Maurizio / Ozgoçmen, Salih / van Gaalen, Floris / Dougados, Maxime. ·Rheumatology B Department, Paris Descartes University, Cochin Hospital, AP-HP, Paris, France INSERM (U1153), Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France. · Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. · ARC, Amsterdam & Atrium MC Heerlen, Amsterdam, The Netherlands. · Department of Rheumatology, Ghent University Hospital, Ghent, Belgium. · Rheumatology Department, Faculty of Medicine, HMC/UMNG, Bogota, Colombia. · Servicio de Reumatologia, Hospital General de México and Universidad Nacional Autonoma de México, México City, Mexico. · Division of Rheumatology, National University Hospital, Singapore, Singapore. · Rheumatology Department, Reina Sofia Hospital; Maimonides Institute for Biomedical Research of Cordoba/University of Cordoba, Cordoba, Spain. · Div Arthritis/Rheumatic Diseases (OPO9), Oregon Health and Science University, Portland, USA. · Department of Rheumatology, Cairo University, Cairo, Egypt. · Russian Academy of Sciences, Moscow, Russia. · Division of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guanzhou, China. · Department of Rheumatology, Mohamed Vth University, URAC 30, El Ayachi Hospital, Salé, Morocco Faculty of Medicine and Pharmacy, Rabat, Morocco. · Rheumazentrum Ruhrgebiet, Herne, Germany. · Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea. · Immuno-Rheumatology Center, St Luke's International Hospital, St Luke's International University, Tokyo, Japan. · Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan. · Department of Rheumatology, University of Coimbra, Coimbra, Portugal University College London, London, UK. · Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. · Rheumatology Section, Instituto de Rehabilitacion Psicofisica and Argentine Rheumatologic Foundation "Dr Osvaldo Carcia Morteo", Buenos Aires, Argentina. · NIHR-Leeds Musculoskeletal Biomedical research Unit, Leeds Institute of Molecular Medicina, University of Leeds, Leeds, UK. · Univerity of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. · Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Erciyes University, Gevher Nesibe Hospital, Kayseri, Turkey. ·Ann Rheum Dis · Pubmed #26489703.

ABSTRACT: BACKGROUND: Increased risk of some comorbidities has been reported in spondyloarthritis (SpA). Recommendations for detection/management of some of these comorbidities have been proposed, and it is known that a gap exists between these and their implementation in practice. OBJECTIVE: To evaluate (1) the prevalence of comorbidities and risk factors in different countries worldwide, (2) the gap between available recommendations and daily practice for management of these comorbidities and (3) the prevalence of previously unknown risk factors detected as a result of the present initiative. METHODS: Cross-sectional international study with 22 participating countries (from four continents), including 3984 patients with SpA according to the rheumatologist. STATISTICAL ANALYSIS: The prevalence of comorbidities (cardiovascular, infection, cancer, osteoporosis and gastrointestinal) and risk factors; percentage of patients optimally monitored for comorbidities according to available recommendations and percentage of patients for whom a risk factor was detected due to this study. RESULTS: The most frequent comorbidities were osteoporosis (13%) and gastroduodenal ulcer (11%). The most frequent risk factors were hypertension (34%), smoking (29%) and hypercholesterolaemia (27%). Substantial intercountry variability was observed for screening of comorbidities (eg, for LDL cholesterol measurement: from 8% (Taiwan) to 98% (Germany)). Systematic evaluation (eg, blood pressure (BP), cholesterol) during this study unveiled previously unknown risk factors (eg, elevated BP (14%)), emphasising the suboptimal monitoring of comorbidities. CONCLUSIONS: A high prevalence of comorbidities in SpA has been shown. Rigorous application of systematic evaluation of comorbidities may permit earlier detection, which may ultimately result in an improved outcome of patients with SpA.

10 Unspecified Report from the Latin American Spondyloarthritis Society for Education and Research in Immunology and Medicine organization 2012 workshop. 2013

Bautista-Molano, Wilson / Toloza, Sergio / Gutiérrez, Marwin / Uribe, Carlos Vinicio Caballero / Pineda, Carlos / Londoño, John / Santos, Pedro / Jaimes, Diego / Diaz, Mario / Chalem, Phillipe / Villota, Orlando / Sierra, Rita / Puche, William / Salas, José / Yara, José / Hamilton, Gordon / Pardo, Carlos / Mercado, Beatriz / Valle-Oñate, Rafael. ·Department of Rheumatology, Hospital Militar, Universidad Militar Nueva Granada/Universidad de La Sabana, Bogotá, Colombia. wbatu@hotmail.com ·J Clin Rheumatol · Pubmed #23965483.

ABSTRACT: The first annual meeting of the Latin American Spondyloarthritis Society for Education and Research in Immunology and Medicine (LASSERIM) was held in Bogotá, Colombia, in September 2012 and was attended by key opinion leaders, researchers, and rheumatologists. The meeting included presentations and discussions from renowned speakers during 2 days and a coaching leadership exercise led by an expert in the field followed by an open forum. Two groups defined a priori discussed the establishment of a professional network and organization to be involved in the identification, assessment, and effective resolution of health care issues in Latin America.A broad spectrum of topics were discussed but focused on the following: pharmacoeconomics in general rheumatology, spondyloarthritis and chronic back pain, therapeutic interventions in rheumatoid arthritis, ultrasonography in spondyloarthritis, impact of social media in medicine and global trends in leadership, quality of life, and innovation. A special workshop on coaching in health care and coaching as a tool to implement LASSERIM goals was part of the 2-day conference.LASSERIM will be working in the future on education, research, and innovation in the field of rheumatology and immunology. A special focus will be on spondyloarthritis, by promoting research, open discussions, and by conducting carefully planned research studies to impact on the quality of life of patients and doctors from Latin American countries.